SOHM, Inc., a pharmaceutical and biotechnology firm that specialising in generic pharmaceuticals, recently celebrated a key milestone by receiving an Official Notice of Patent Allowance from Japan's Patent Office. SOHM is now stronger in the rapidly growing market for genome editing thanks to patent No. 2023-121860,  called "CAS 9 Retroviral Integrase and CAS 9 Recombinase Systems for Targeted Incorporation of a DNA Sequence into the Genome of a Cell or Organism.

"This recently granted patent protects SOHM's ABBIE (A Base Binding Integrase Enzyme) Genome Editing technology, known as SAGE (SOHM ABBIE Genome Editing). SAGE is a new approach to gene editing that provides safe and effective methods for making targeted changes to genomic DNA. It permits the precise insertion of exogenous DNA into endogenous genomic regions, paving the path for game-changing applications in biotechnology, synthetic biology, and precision medicine. 

Dr. David C. Aguilar, Chief Operating Officer of SOHM, emphasized the significance of this achievement, saying, "The SOHM-ABBIE teams are fully committed to providing precision delivery of large DNA payloads without inducing double-stranded genomic breaks, which are common in other genome editing technologies and frequently lead to toxic events." This patent not only strengthens our intellectual property strategy and portfolio, but it also creates new prospects for collaborative product development and expansion in Japan, Korea, China, Indo-Asiatic, Pacific Rim, and American markets." 

The biotechnology industry views the ABBIE Genome Editing platform as a game changer. SAGE improves safety and efficacy by avoiding double-stranded breaks, which are a significant issue in genomic editing. This novel approach has important implications for the development of medicines for cancer, congenital defects, and other diseases. =

SOHM's patent approval in Japan boosts its position in a competitive and rapidly increasing sector. Precedence Market Research predicts that the worldwide cell treatment market will expand from $4.5 billion in 2023 to $97 billion by 2033; hence, the timing of this patent is critical. 

The patent allows SOHM to out-license its ABBIE technology and increase sales of its SAGE R&D kits, modified cell lines, and rapid drug screening assays. These items enable the creation of recombinant biotherapeutics for human and animal health, as well as synthetic biology applications involving microbial and plant cells. 

SOHM's ABBIE technology establishes them as a strong competitor in the rapidly developing genome editing business, which already includes over 120 companies. By providing a viable alternative to existing CRISPR-based technologies, SOHM positions itself to accelerate advances in precision medicine and synthetic biology.

According to Dr. Aguilar, our Japanese patent allowance covers this biotechnology, which facilitates the development of transformative therapies. "It could lead to long-term remissions and tumour regressions in cancer, as well as potential cures for other diseases." 

SOHM intends to use this patent to extend its marketing and sales operations in major worldwide regions such as Japan, Korea, China, the European Union, and the Americas. The company is also looking at strategic alliances and collaborations to help speed the commercialization of its SAGE-based products and services.